ANAPTYSBIO, INC (ANAB)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, ANAPTYSBIO, INC reported revenue of $234.60M, up 157.0% from the prior year. The company ran a net loss, with a net margin of -5.6%.
Key ratios (FY2025)
20.4%
Operating margin
-5.6%
Net margin
-35.6%
Return on equity
+157.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $234.60M | $91.28M | $17.16M | $10.29M | $63.17M | $75.00M | $8.00M | $5.00M | $10.00M | — |
| Operating Income | $47.90M | -$114.95M | -$164.41M | -$115.15M | -$56.81M | -$23.88M | -$107.43M | -$66.72M | -$28.78M | -$3.02M |
| Net Income | -$13.23M | -$145.23M | -$163.62M | -$128.72M | -$57.80M | -$19.93M | -$97.34M | -$61.66M | -$30.07M | -$4.26M |
| EPS (Diluted) | $-0.46 | $-5.12 | $-6.08 | $-4.57 | $-2.11 | $-0.73 | $-3.60 | $-2.50 | $-1.52 | $-1.62 |
| Total Assets | $364.39M | $483.83M | $452.39M | $610.38M | $643.07M | $416.55M | $435.20M | $509.00M | $329.36M | $62.18M |
| Shareholders' Equity | $37.21M | $70.87M | $88.10M | $262.10M | $356.43M | $396.73M | $405.01M | $486.37M | $307.58M | -$38.25M |
| Cash & Equivalents | $238.20M | $123.08M | $35.97M | $71.31M | $495.73M | $250.46M | $171.02M | $113.60M | $81.19M | $51.23M |
| Operating Cash Flow | $19.70M | -$135.34M | -$120.80M | -$73.59M | -$45.92M | -$14.16M | -$69.52M | -$48.51M | -$19.44M | -$9.03M |
| Capital Expenditures | $87.0K | $358.0K | $807.0K | $358.0K | $1.37M | $569.0K | $805.0K | $1.06M | $290.0K | $50.0K |
| Shares Outstanding | 28.02M | 30.47M | 26.60M | 28.51M | 27.65M | 27.36M | 27.25M | 26.92M | 23.79M | 2.65M |